{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:44:22Z","timestamp":1791233062174,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T00:00:00Z","timestamp":1633824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T00:00:00Z","timestamp":1633824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-021-02285-0","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T03:37:32Z","timestamp":1633923452000},"page":"759-766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Down-regulated expression of miR-582 predicts poor prognosis and facilitates melanoma progression by targeting FOXC1"],"prefix":"10.1007","volume":"314","author":[{"given":"Fang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,10]]},"reference":[{"issue":"6","key":"2285_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000446716","volume":"39","author":"C Bender","year":"2016","unstructured":"Bender C, Hassel JC, Enk A (2016) Immunotherapy of melanoma. Oncol Res Treat 39(6):369\u2013376. https:\/\/doi.org\/10.1159\/000446716","journal-title":"Oncol Res Treat"},{"issue":"3","key":"2285_CR2","first-page":"163","volume":"27","author":"L Lugovi\u0107-Mihi\u0107","year":"2019","unstructured":"Lugovi\u0107-Mihi\u0107 L, \u0106esi\u0107 D, Vukovi\u0107 P, Novak Bili\u0107 G, \u0160itum M, \u0160poljar S (2019) Melanoma development: current knowledge on melanoma pathogenesis. Acta Dermatovenerol Croat ADC 27(3):163\u2013168","journal-title":"Acta Dermatovenerol Croat ADC"},{"issue":"10","key":"2285_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1043\/0003-9985(2001)125<1295:mm>2.0.co;2","volume":"125","author":"A Slominski","year":"2001","unstructured":"Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC (2001) Malignant melanoma. Arch Pathol Lab Med 125(10):1295\u20131306. https:\/\/doi.org\/10.1043\/0003-9985(2001)125%3c1295:mm%3e2.0.co;2","journal-title":"Arch Pathol Lab Med"},{"key":"2285_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/ott.s146663","volume":"11","author":"H Duan","year":"2018","unstructured":"Duan H, Jiang K, Wei D, Zhang L, Cheng D, Lv M, Xu Y, He A (2018) Identification of epigenetically altered genes and potential gene targets in melanoma using bioinformatic methods. Onco Targets Ther 11:9\u201315. https:\/\/doi.org\/10.2147\/ott.s146663","journal-title":"Onco Targets Ther"},{"key":"2285_CR5","doi-asserted-by":"publisher","first-page":"9975","DOI":"10.2147\/ott.s225120","volume":"12","author":"C Shen","year":"2019","unstructured":"Shen C, Hua H, Gu L, Cao S, Cai H, Yao X, Chen X (2019) miR-124 functions as a melanoma tumor suppressor by targeting RACK1. Onco Targets Ther 12:9975\u20139986. https:\/\/doi.org\/10.2147\/ott.s225120","journal-title":"Onco Targets Ther"},{"key":"2285_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/978-3-642-38007-5_25","volume":"159","author":"AM Grimaldi","year":"2014","unstructured":"Grimaldi AM, Cassidy PB, Leachmann S, Ascierto PA (2014) Novel approaches in melanoma prevention and therapy. Cancer Treat Res 159:443\u2013455. https:\/\/doi.org\/10.1007\/978-3-642-38007-5_25","journal-title":"Cancer Treat Res"},{"issue":"6","key":"2285_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/cmr.0000000000000496","volume":"28","author":"I Tromme","year":"2018","unstructured":"Tromme I, Sacr\u00e9 L, Hammouch F, Richez P, Degryse JM, Speybroeck N (2018) Melanoma diagnosis: predictive value of macroscopic changes observed by the patient. Melanoma Res 28(6):611\u2013617. https:\/\/doi.org\/10.1097\/cmr.0000000000000496","journal-title":"Melanoma Res"},{"issue":"2","key":"2285_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3892\/ol.2019.10453","volume":"18","author":"FC Ma","year":"2019","unstructured":"Ma FC, He RQ, Lin P, Zhong JC, Ma J, Yang H, Hu XH, Chen G (2019) Profiling of prognostic alternative splicing in melanoma. Oncol Lett 18(2):1081\u20131088. https:\/\/doi.org\/10.3892\/ol.2019.10453","journal-title":"Oncol Lett"},{"issue":"5","key":"2285_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3892\/ol.2020.12045","volume":"20","author":"XY Zhang","year":"2020","unstructured":"Zhang XY, Zhang PY (2020) Genetics and epigenetics of melanoma. Oncol Lett 20(5):184. https:\/\/doi.org\/10.3892\/ol.2020.12045","journal-title":"Oncol Lett"},{"issue":"2","key":"2285_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3892\/etm.2019.7644","volume":"18","author":"C Zhang","year":"2019","unstructured":"Zhang C, Li H, Wang J, Zhang J, Hou X (2019) MicroRNA-338-3p suppresses cell proliferation, migration and invasion in human malignant melanoma by targeting MACC1. Exp Ther Med 18(2):997\u20131004. https:\/\/doi.org\/10.3892\/etm.2019.7644","journal-title":"Exp Ther Med"},{"issue":"1","key":"2285_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/cbm-190289","volume":"26","author":"D Huang","year":"2019","unstructured":"Huang D, Wang F, Wu W, Lian C, Liu E (2019) MicroRNA-429 inhibits cancer cell proliferation and migration by targeting the AKT1 in melanoma. Cancer Biomark 26(1):63\u201368. https:\/\/doi.org\/10.3233\/cbm-190289","journal-title":"Cancer Biomark"},{"issue":"6","key":"2285_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/cbm-2012-0274","volume":"11","author":"M Sand","year":"2012","unstructured":"Sand M, Sand D, Altmeyer P, Bechara FG (2012) MicroRNA in non-melanoma skin cancer. Cancer Biomark 11(6):253\u2013257. https:\/\/doi.org\/10.3233\/cbm-2012-0274","journal-title":"Cancer Biomark"},{"issue":"5","key":"2285_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","volume":"75","author":"RC Lee","year":"1994","unstructured":"Lee RC, Feinbaum RL, Ambros V (1994) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843\u2013854","journal-title":"Cell"},{"issue":"24","key":"2285_CR14","doi-asserted-by":"publisher","first-page":"15524","DOI":"10.1073\/pnas.242606799","volume":"99","author":"GA Calin","year":"2002","unstructured":"Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99(24):15524\u201315529. https:\/\/doi.org\/10.1073\/pnas.242606799","journal-title":"Proc Natl Acad Sci USA"},{"key":"2285_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.628367","volume":"10","author":"A Ray","year":"2020","unstructured":"Ray A, Kunhiraman H, Perera RJ (2020) The paradoxical behavior of microRNA-211 in melanomas and other human cancers. Front Oncol 10:628367. https:\/\/doi.org\/10.3389\/fonc.2020.628367","journal-title":"Front Oncol"},{"issue":"8","key":"2285_CR16","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/jid.2010.63","volume":"130","author":"S Caramuta","year":"2010","unstructured":"Caramuta S, Egyh\u00e1zi S, Rodolfo M, Witten D, Hansson J, Larsson C, Lui WO (2010) MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Investig Dermatol 130(8):2062\u20132070. https:\/\/doi.org\/10.1038\/jid.2010.63","journal-title":"J Investig Dermatol"},{"issue":"6","key":"2285_CR17","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1177\/1533034617737923","volume":"16","author":"J Peng","year":"2017","unstructured":"Peng J, Liu H, Liu C (2017) MiR-155 promotes uveal melanoma cell proliferation and invasion by regulating NDFIP1 expression. Technol Cancer Res Treat 16(6):1160\u20131167. https:\/\/doi.org\/10.1177\/1533034617737923","journal-title":"Technol Cancer Res Treat"},{"key":"2285_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.104348","volume":"112","author":"J Arnold","year":"2020","unstructured":"Arnold J, Engelmann JC, Schneider N, Bosserhoff AK, Kuphal S (2020) miR-488-5p and its role in melanoma. Exp Mol Pathol 112:104348. https:\/\/doi.org\/10.1016\/j.yexmp.2019.104348","journal-title":"Exp Mol Pathol"},{"issue":"5","key":"2285_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11427-017-9138-9","volume":"61","author":"N Lv","year":"2018","unstructured":"Lv N, Hao S, Luo C, Abukiwan A, Hao Y, Gai F, Huang W, Huang L, Xiao X, Eichm\u00fcller SB, He D (2018) miR-137 inhibits melanoma cell proliferation through downregulation of GLO1. Sci China Life Sci 61(5):541\u2013549. https:\/\/doi.org\/10.1007\/s11427-017-9138-9","journal-title":"Sci China Life Sci"},{"issue":"6","key":"2285_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41419-019-1620-3","volume":"10","author":"F Li","year":"2019","unstructured":"Li F, Li X, Qiao L, Liu W, Xu C, Wang X (2019) MALAT1 regulates miR-34a expression in melanoma cells. Cell Death Dis 10(6):389. https:\/\/doi.org\/10.1038\/s41419-019-1620-3","journal-title":"Cell Death Dis"},{"issue":"8","key":"2285_CR21","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41418-017-0053-8","volume":"25","author":"M Luo","year":"2018","unstructured":"Luo M, Wu L, Zhang K, Wang H, Zhang T, Gutierrez L, O\u2019Connell D, Zhang P, Li Y, Gao T, Ren W, Yang Y (2018) miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. Cell Death Differ 25(8):1457\u20131472. https:\/\/doi.org\/10.1038\/s41418-017-0053-8","journal-title":"Cell Death Differ"},{"issue":"12","key":"2285_CR22","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1158\/0008-5472.can-15-2932","volume":"76","author":"CE Weber","year":"2016","unstructured":"Weber CE, Luo C, Hotz-Wagenblatt A, Gardyan A, Korda\u00df T, Holland-Letz T, Osen W, Eichm\u00fcller SB (2016) miR-339-3p is a tumor suppressor in melanoma. Can Res 76(12):3562\u20133571. https:\/\/doi.org\/10.1158\/0008-5472.can-15-2932","journal-title":"Can Res"},{"issue":"1","key":"2285_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-020-01208-3","volume":"19","author":"M Xie","year":"2020","unstructured":"Xie M, Yu T, Jing X, Ma L, Fan Y, Yang F, Ma P, Jiang H, Wu X, Shu Y (2020) Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p\/HUR\/VEGF axis and suppressing HSP90 degradation. Mol Cancer 19(1):112. https:\/\/doi.org\/10.1186\/s12943-020-01208-3","journal-title":"Mol Cancer"},{"key":"2285_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.omtn.2019.01.004","volume":"16","author":"S Huang","year":"2019","unstructured":"Huang S, Zou C, Tang Y, Wa Q, Peng X, Chen X, Yang C, Ren D, Huang Y, Liao Z, Huang S, Zou X, Pan J (2019) miR-582-3p and miR-582-5p suppress prostate cancer metastasis to bone by repressing TGF-\u03b2 signaling. Mol Ther Nucleic acids 16:91\u2013104. https:\/\/doi.org\/10.1016\/j.omtn.2019.01.004","journal-title":"Mol Ther Nucleic acids"},{"key":"2285_CR25","doi-asserted-by":"publisher","first-page":"11933","DOI":"10.2147\/cmar.s274835","volume":"12","author":"T Xu","year":"2020","unstructured":"Xu T, Tian Y, Guan Y, Su Y, Luo W, Yang G, Zhang Y (2020) MiR-582-5p inhibits bladder cancer-genesis by suppressing TTK expression. Mol Cancer 12:11933\u201311944. https:\/\/doi.org\/10.2147\/cmar.s274835","journal-title":"Mol Cancer"},{"issue":"22","key":"2285_CR26","doi-asserted-by":"publisher","first-page":"7760","DOI":"10.26355\/eurrev_201811_16397","volume":"22","author":"LL Wang","year":"2018","unstructured":"Wang LL, Zhang M (2018) miR-582-5p is a potential prognostic marker in human non-small cell lung cancer and functions as a tumor suppressor by targeting MAP3K2. Eur Rev Med Pharmacol Sci 22(22):7760\u20137767. https:\/\/doi.org\/10.26355\/eurrev_201811_16397","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"2285_CR27","doi-asserted-by":"publisher","first-page":"8309","DOI":"10.1007\/s13277-015-3582-0","volume":"36","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Huang W, Ran Y, Xiong Y, Zhong Z, Fan X, Wang Z, Ye Q (2015) miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. Tumour Biol 36(11):8309\u20138316. https:\/\/doi.org\/10.1007\/s13277-015-3582-0","journal-title":"Tumour Biol"},{"key":"2285_CR28","doi-asserted-by":"publisher","first-page":"11933","DOI":"10.2147\/cmar.s274835","volume":"12","author":"Y Tian","year":"2020","unstructured":"Tian Y, Guan Y, Su Y, Luo W, Yang G, Zhang Y (2020) MiR-582-5p inhibits bladder cancer-genesis by suppressing TTK expression. Cancer Manag Res 12:11933\u201311944. https:\/\/doi.org\/10.2147\/cmar.s274835","journal-title":"Cancer Manag Res"},{"issue":"21","key":"2285_CR29","doi-asserted-by":"publisher","first-page":"11026","DOI":"10.26355\/eurrev_202011_23587","volume":"24","author":"CY Ye","year":"2020","unstructured":"Ye CY, Zheng CP, Zhou WJ, Weng SS (2020) MiR-582-5p inhibits the growth and invasion of osteosarcoma cell by targeting NOVA1. Eur Rev Med Pharmacol Sci 24(21):11026\u201311031. https:\/\/doi.org\/10.26355\/eurrev_202011_23587","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"2285_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.sjbs.2018.03.007","volume":"25","author":"L Li","year":"2018","unstructured":"Li L, Ma L (2018) Upregulation of miR-582-5p regulates cell proliferation and apoptosis by targeting AKT3 in human endometrial carcinoma. Saudi J Biol Sci 25(5):965\u2013970. https:\/\/doi.org\/10.1016\/j.sjbs.2018.03.007","journal-title":"Saudi J Biol Sci"},{"issue":"8","key":"2285_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/jjco\/hyx073","volume":"47","author":"WW Wang","year":"2017","unstructured":"Wang WW, Chen B, Lei CB, Liu GX, Wang YG, Yi C, Wang YY, Zhang SY (2017) miR-582-5p inhibits invasion and migration of salivary adenoid cystic carcinoma cells by targeting FOXC1. Jpn J Clin Oncol 47(8):690\u2013698. https:\/\/doi.org\/10.1093\/jjco\/hyx073","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"2285_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13046-018-0894-0","volume":"37","author":"S Cao","year":"2018","unstructured":"Cao S, Wang Z, Gao X, He W, Cai Y, Chen H, Xu R (2018) FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC. J Exp Clin Cancer Res CR 37(1):220. https:\/\/doi.org\/10.1186\/s13046-018-0894-0","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"7","key":"2285_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41389-018-0061-7","volume":"7","author":"R Subramani","year":"2018","unstructured":"Subramani R, Camacho FA, Levin CI, Flores K, Clift A, Galvez A, Terres M, Rivera S, Kolli SN, Dodderer J, Miranda M, Rodriguez A, Pedroza DA, Chatterjee A, Lakshmanaswamy R (2018) FOXC1 plays a crucial role in the growth of pancreatic cancer. Oncogenesis 7(7):52. https:\/\/doi.org\/10.1038\/s41389-018-0061-7","journal-title":"Oncogenesis"},{"issue":"4","key":"2285_CR34","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.3892\/etm.2018.6627","volume":"16","author":"Z Liu","year":"2018","unstructured":"Liu Z, Xu S, Chu H, Lu Y, Yuan P, Zeng X (2018) Silencing FOXC1 inhibits growth and migration of human oral squamous cell carcinoma cells. Exp Ther Med 16(4):3369\u20133376. https:\/\/doi.org\/10.3892\/etm.2018.6627","journal-title":"Exp Ther Med"},{"issue":"51","key":"2285_CR35","doi-asserted-by":"publisher","first-page":"84375","DOI":"10.18632\/oncotarget.11224","volume":"7","author":"J Wang","year":"2016","unstructured":"Wang J, Li L, Liu S, Zhao Y, Wang L, Du G (2016) FOXC1 promotes melanoma by activating MST1R\/PI3K\/AKT. Oncotarget 7(51):84375\u201384387. https:\/\/doi.org\/10.18632\/oncotarget.11224","journal-title":"Oncotarget"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-021-02285-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T17:11:34Z","timestamp":1661274694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-021-02285-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,10]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["2285"],"URL":"https:\/\/doi.org\/10.1007\/s00403-021-02285-0","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,10]]},"assertion":[{"value":"8 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of Binzhou Medical University Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participant has consented to the submission of the case report to the journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}